Data Suggest Interim PET2 Scans Can be Omitted for Frontline Brentuximab Vedotin Regimens in Hodgkin Lymphoma
The incorporation of brentuximab vedotin (Adcetris) into the frontline treatment of patients with Hodgkin lymphoma correlates with superior efficacy, irrespective of PET2 results, suggesting loss of predictive value with the scan.
United States Ravand Samaeekia Loma Linda University Internal Medicine International Prognostic Score Loma Linda University Cancer Center Loma Linda University Cancer
Source: onclive.com